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BACKGROUND. Despite the high incidence and serious consequences of skeletal metastasis
in prostate cancer patients, the mechanisms involved in establishing secondary lesions in bone
are not well-understood. In this study, the role of the mineralized bone matrix in the process
of skeletal metastasis was evaluated.
METHODS. Attachment, migration, and proliferation responses of human prostate cancer
cells to a crude bone protein extract (CBE) were studied. LNCaP and DU145 cells were
utilized in 24-hr attachment assays. Boyden chamber chemotactic assays and cell proliferation
assays utilized DU145 cells.
RESULTS. CBE and fibronectin (FN) promoted attachment of DU145 cells, whereas only FN
facilitated attachment of LNCaP cells. CBE-mediated adhesion of DU145 cells was reduced by
94% with cycloheximide, by 98% with RGD peptides, and by 94% with an antibody to avb3.
Although DU145 cells migrated toward FN, CBE did not promote migration of DU145 cells.
DU145 cells grown in the presence of CBE-containing media demonstrated a significant
reduction in cell number by day 4. The antiproliferative effect of CBE was not due to cell
toxicity.
CONCLUSIONS. In conclusion, results from this study indicate that mineralized bone pro-
teins promote the attachment of DU145 cells in vitro and suggest that bone proteins may play
a key role in vivo during the development of metastatic prostate lesions in bone. Prostate
36:14–22, 1998. © 1998 Wiley-Liss, Inc.
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INTRODUCTION
The incidence of and mortality from prostate cancer
are increasing yearly in the United States, with an es-
timated 224,000 new cases and 40,000 deaths attrib-
uted to the disease in 1995 [1]. A significant event
contributing to morbidity and mortality associated
with prostate cancer is the development of skeletal
metastasis. Epidemiological data indicate that 70% of
prostate cancer patients develop secondary metastatic
lesions in bone [2]. An effective therapy for the treat-
ment of skeletal metastases has yet to be developed, in
part due to an incomplete understanding of the pre-
cise mechanisms involved in the development of sec-
ondary tumors in bone.
Several cells located in bone have been implicated
in the pathogenesis of skeletal metastasis in prostate
cancer. Haq et al. [3] reported that bone marrow-
derived endothelial cells support preferential attach-
ment of rat prostate cancer cells in vitro, suggesting
that bone marrow sinusoidal capillaries play an active
role in recruitment of prostate cancer cells to bone.
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Utilizing a mouse coinoculation model, Gleave et al.
[4] showed that bone fibroblasts enhance the growth
of human prostate cancer cells in vivo, suggesting that
bone stromal cells may also play a role in skeletal
metastases. Osteoblasts, being a rich source of growth
factors, have also been implicated as a cell type in-
volved in the pathogenesis of skeletal metastases by
promoting growth [5] and attachment [3] of prostate
cancer cells. Importantly, factors secreted by osteo-
blasts as well as circulating factors are entrapped in
bone and provide a rich source of growth factors to
facilitate the proliferation of tumor cells in the bone
microenvironment. For example, insulin-like growth
factor I (IGF-I), found in high concentrations in bone,
stimulates DNA synthesis in [6,7], and migration of
[7], human prostate cancer cells in vitro. Thus, bone
provides an environment with the potential to attract
and subsequently promote the growth of prostate
cells.
Although a variety of mechanisms have been pro-
posed to be involved in the development of bone me-
tastases, the role of the mineralized bone matrix has
not been determined. Recent results by Ritchie et al.
[7] indicate that when bone-derived factors are evalu-
ated individually, they have variable effects on migra-
tion and proliferation of several human prostate can-
cer cell lines in vitro, including DU145 cells. For ex-
ample, IGF-I and IGF-II enhanced prostate cancer cell
proliferation, whereas TGFb induced a biphasic pro-
liferative response. In order to investigate a potentially
more pathophysiologic situation, a crude mixture of
endogenous proteins extracted from bone was utilized
in the present study. In addition to growth factors, it is
well-established that bone is a rich source for several
other molecules. These additional molecules include
chemotactic and attachment factors such as fibronectin
(FN), collagen, bone salioprotein (BSP), and osteopon-
tin (OPN) [8]. The use of crude bone protein extract
(CBE) in this study allowed us to assess the net effect
of the many proteins present in bone on several key
events in the pathogenesis of prostate cancer metasta-
sis to bone.
We hypothesized that proteins contained within
the mineralized bone matrix would stimulate prostate
cancer cells to exhibit responses crucial to establishing
secondary lesions. These critical responses were tumor
cell migration, attachment, and proliferation. To test
this hypothesis, the ability of CBE to promote the at-
tachment of an androgen-dependent human prostate
cancer cell line (LNCaP cells) and an androgen-
independent human prostate cancer cell line (DU145
cells) was evaluated. Results demonstrated a 5–10-fold
increase in CBE-mediated attachment of DU145 cells
when compared to CBE-mediated attachment of
LNCaP cells. Given that DU145 cells demonstrated the
stronger response to bone proteins, DU145 cells were
selected for further evaluation of the effects of crude
bone extracts (CBE) on adhesion, migration, and pro-
liferation of prostate cancer cells. Results indicate that
crude protein extracts of bone promote attachment of
DU145 cells in vitro, and suggest that proteins within




DU145 cells were originally isolated from a human
prostate adenocarcinoma patient in 1976 [9]. Extensive
tumor metastasis to the vertebral column and right
femoral neck was observed in this patient. Additional
metastases to lymph nodes, liver, lungs, and brain
were also noted. The DU145 cell line was established
from a central nervous system lesion. Importantly, no
additional primary carcinomas were found. DU145
cells were provided by Dr. Ken Pienta (SPORE in Pros-
tate Cancer at the University of Michigan). DU145
cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM/F12), 10% FBS, 100 units/ml peni-
cillin, and 100 mg/ml streptomycin (all culture re-
agents from GIBCO/BRL Life Technologies, Inc.,
Grand Island, NY). Cells were not used beyond pas-
sage 50. Experiments were conducted with DU145
cells at 70–80% confluency.
LNCaP cells were originally isolated from a human
prostate adenocarcinoma patient in 1977 [10]. Dis-
seminated bony metastases were found on bone scan,
with metastases to lymph nodes also noted. The
LNCaP cell line was established from a supraclavicu-
lar lymph node lesion. LNCaP cells were obtained
from UroCor, Inc. (Oklahoma City, OK) and main-
tained in T-medium containing 5% FBS, 100 units/ml
penicillin, and 100 mg/ml streptomycin, as recom-
mended by UroCor. Experiments were conducted
with LNCaP cells at 70–80% confluency.
Preparation of Crude Bone Extracts (CBE)
The procedure outlined here has been previously
described in detail [11,12]. Briefly, bone fragments
from bovine femurs were washed for 2 days with
phosphate-buffered saline containing protease inhibi-
tors (pH 7.4, 4°C). Bone proteins were extracted with 4
M guanidine-HCL at 4°C for 7 days, followed by 4 M
guanidine-HCL/ethylenediaminetetraacetic acid
(EDTA) at 4°C for 7 days. Both guanidine extractions
were performed in the presence of protease inhibitors
(0.05 M 6-aminohexanoic acid, 0.005 M benzamidine
HCL, and 0.001 M phenylmethylsufonyl fluoride),
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previously demonstrated to prevent protein degrada-
tion during extraction procedures [12]. Extracts were
then gravity-filtered and concentrated by ultrafiltra-
tion under pressure. Concentrated extracts were dia-
lyzed against distilled water and lyophilized. Samples
were stored at −20°C. Studies utilized 4 M guanidine-
HCL/EDTA extracts, containing proteins bound to
the mineral phase.
RNA Extraction and Northern Blot Analysis
Total RNA was extracted from DU145 cells at 80%
confluency, using a modified guanidinium isothiocya-
nate procedure [13]. Total RNA (20 mg) was separated
electrophoretically in a 1% agarose-5% formaldehyde
gel. RNA was then transferred to a Duralon-UV mem-
brane (Stratagene, La Jolla, CA) and immobilized by
UV crosslinking. Membranes were hybridized over-
night at 42°C with 32P cDNA probes for human av
and b3 integrin subunits (cDNAs kindly provided by
Dr. Gideon Rodan, Merck and Company Inc., West
Point, PA). After a wash at high stringency, the blots
were exposed to XOMAT film (Eastman Kodak Co.,
Rochester, NY) for 5 days at −70°C.
Cell Adhesion Assay
Twenty-four-well Falcon plastic plates (Becton
Dickinson, Lincoln Park, NJ) were precoated with 400
ml of the putative attachment agent at the following
concentrations: fibronectin (FN) 20 mg/ml (Sigma
Chemical Co., St. Louis, MO), CBE 20 mg/ml and 50
mg/ml, or water as a negative control. Tissue culture
plates served as a positive control. After coatings had
dried, the dishes were preincubated with serum-free
DMEM/F12 containing 0.1% bovine serum albumin
(BSA) for 1 hr at 37°C. Following the preincubation
period, 20,000–30,000 cells were added to the wells,
and attachment was evaluated at 4 and 24 hr. Unat-
tached cells were removed by rinsing the wells twice
with Hank’s balanced salt solution. Cells were visual-
ized for extent of cell spreading, and photos were
taken. Attached cells were removed with trypsin/
EDTA, and any cell aggregates were gently agitated
with a pipette until these aggregates were no longer
observed under the microscope. Individual cells were
then quantitated with a Coulter counter (Coulter Cor-
poration, Miami, FL). The mechanism(s) of bone ex-
tract and fibronectin-mediated cell adhesion were
evaluated with the addition of one of the following
during the preincubation period: cycloheximide (10
mg/ml, Sigma Chemical Co.), arginine-glycine-
aspartic acid (RGD) or arginine-glycine-glutamic acid
(RGE) peptides (100 mg/ml, University of Michigan
Biomedical Research Core Facilities), murine mono-
clonal antibody to avb3 (LM609) (100 mg/ml, pro-
vided by David E. Cheresh, The Scripps Research In-
stitute La Jolla, CA), rabbit monoclonal antibody to
human FN (100 mg/ml, GIBCO), mouse IgG (100 mg/
ml, Sigma Chemical Co.), and rabbit IgG (100 mg/ml,
Sigma Chemical Co.). Dose selection for each reagent
was based on previous studies [14,15]. All attachment
conditions were evaluated in triplicate, and experi-
ments were conducted on at least three separate occa-
sions.
Cell Migration Assay
A Boyden chamber chemotactic assay [16] was uti-
lized in which the lower chamber contained the puta-
tive chemotactic agent dissolved in serum-free
DMEM/F12/0.1% BSA media at the following con-
centrations: CBE at 20 and 50 mg/ml, osteopontin fu-
sion protein (GST-OPN) at 20 and 50 mg/ml, and FN
at 20 mg/ml. (GST-OPN was prepared using the
method of Xuan et al. [14]). Nuclepore polycarbonate
membranes (Costar Corporation, Cambridge, MA)
with 8.0-mm diameter pores were precoated with a
solution containing 0.002% swine gelatin and 0.5%
acetic acid for 1 hr at 90°C and allowed to dry over-
night. The membranes were then placed between the
lower and upper chambers. Subconfluent cells
(20,000–25,000) were added to the upper chamber in
serum-free DMEM/F12/0.1% BSA media. Chemotac-
tic activity was evaluated at 3, 6, and 24 hr. Mem-
branes were removed, fixed in methanol, and stained
with hematoxylin and eosin. The upper surface of the
membrane was gently swabbed to remove cells which
had not migrated through the membrane. Migrated
cells were then counted in five nonoverlapping fields
per membrane with light microscopy (100× magnifi-
cation) and averaged. All chemotactic conditions were
evaluated in triplicate. Chemotaxis experiments were
conducted on three separate occasions.
Proliferation Assay
DU145 cells were seeded at 5,000 cells/well in 24-
well tissue culture dishes and grown overnight in 10%
FBS DMEM/F12 media. Media were removed the next
day and the wells were washed with phosphate-
buffered saline (PBS), to remove any unattached cells.
Next, on day 0, the cells were incubated in DMEM/
F12 under the following conditions, in triplicate: 10%
FBS, 2% FBS, or 2% FBS plus CBE (20 mg/ml). Media
were changed on day 2. Proliferation was assessed on
days 1, 2, and 4 by removing the media and rinsing the
wells twice with Hank’s balanced salt solution to re-
move the unattached cells. Attached cells were re-
moved with trypsin/EDTA, and any cell aggregates
were gently agitated with a pipette until these aggre-
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gates were no longer observed under the microscope.
Individual cells were then quantitated with a Coulter
counter. Proliferation experiments were conducted on
three separate occasions.
Statistics
The unpaired t-test (two-tailed; P < 0.05) was em-
ployed to compare mean experimental values with the
corresponding control values.
RESULTS
Effect of CBE on DU145 and LNCaP Cell
Adhesion
Twenty-four-hour attachment results demonstrated
that CBE promoted attachment of DU145 cells
(P < 0.005) when compared to water-coated controls
(Fig. 1). Although fibronectin promoted attachment of
LNCaP cells (P < 0.05), CBE did not facilitate attach-
ment of LNCaP cells. Furthermore, attachment results
indicated that, under all conditions evaluated, the per-
cent attachment of LNCaP cells was substantially
lower than percent attachment of DU145 cells. Given
that DU145 cells demonstrated a stronger attachment
profile and that CBE promoted attachment of these
cells, CBE-facilitated adhesion, migration and prolif-
eration were further characterized utilizing DU145
cells only.
Morphologic observations 4 hr following plating of
DU145 cells suggested that aggregation of cells oc-
curred in water-coated and CBE-coated wells, with
weak attachment of these aggregates in the CBE-
coated wells (minimal cell spreading on the plates was
observed). In contrast, cells exposed to fibronectin
were uniformly dispersed in wells, with no evidence
of cell aggregation at 4 hr. In addition, cells demon-
strated a greater extent of spreading on fibronectin-
coated dishes when compared with cells on control or
CBE-coated wells at 4 hr. Morphologic evaluation of
cells at 24 hr demonstrated that the cell aggregates on
CBE-coated wells had established a firmly attached/
spread morphology, while cells on uncoated dishes
failed to exhibit properties of cell attachment/
spreading (Fig. 2). Attachment of cells in dishes coated
with CBE at 20 mg/ml was similar to that at 50 mg/ml
(data not shown). Cells grown on FN-coated dishes for
24 hr maintained the uniform dispersion pattern ob-
served at 4 hr and were firmly attached to the dishes.
To further characterize the dynamics of DU145 cell
adhesion on CBE-coated dishes, the role of protein
synthesis in this process was assessed. The addition of
cycloheximide to the preincubation media signifi-
cantly reduced adhesion of DU145 cells to all sub-
strates examined (Fig. 3), including CBE, which dem-
onstrated a 94% reduction in attachment, indicating
that cell adhesion to CBE requires protein synthesis.
Fig. 1. CBE-mediated attachment of LNCaP and DU145 cells.
Cells were plated on tissue culture plates (TCT) or plastic plates
precoated with one of the following: water, 20 µg/ml fibronectin
(FN), or 20 µg/ml crude bone extract (CBE). After 24 hr, unat-
tached cells were removed and attached cells were quantitat-
ed with a Coulter counter. Data are expressed as mean ± SD
of triplicate plates. CBE promoted attachment of DU145 cells
(*P < 0.005). FN promoted attachment of LNCaP cells
(**P < 0.05), while CBE did not. LNCaP cells demonstrated a
lower level of attachment in each condition evaluated when com-
pared to DU145 cells.
Fig. 2. Phase-contrast light photomicrographs demonstrating
DU145 cell morphology, following 24-hr incubation on CBE-
coated plates. A: DU145 cells incubated on plastic plates pre-
coated with water remained rounded and unattached. B: DU145
cells incubated with 20 µg/ml crude bone extract adhered and
spread on the plates. Attachment morphology was also evaluated
with the addition of RGD (C) or RGE (D) peptides (100 µg/ml) to
the preincubation media. RGD peptides blocked CBE-mediated
attachment and spreading, while cells incubated in the presence of
RGE peptides attached and spread on CBE coated plates (100×).
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Cycloheximide also significantly reduced attachment
of DU145 cells to fibronectin; however, protein syn-
thesis inhibition was less effective, with only a 45%
reduction in cell attachment observed. Cell adhesion
to CBE was RGD-dependent (Fig. 4), as the addition of
RGD peptides reduced cell adhesion to CBE coated
dishes by 98%. The control RGE peptides did not sig-
nificantly alter cell adhesion. RGD peptides also sig-
nificantly reduced cell attachment to FN-coated
dishes; however, as with the cyloheximide treatment,
RGD blockade was less effective in FN-coated wells,
as indicated by only a 27% reduction in attachment. In
addition, cell adhesion to CBE-coated dishes was
nearly abolished by the monoclonal antibody to avb3
(LM609), with a 94% reduction observed. An antibody
to FN completely blocked FN-mediated attachment of
DU145 cells (98% reduction), while reducing CBE-
mediated attachment by only 38% (Fig. 5). No effect on
CBE-mediated cell attachment was observed with
mouse or rabbit IgG control antibodies (data not
shown).
DU145 Cell Chemotaxis
To determine the chemotactic response of DU145
cells to CBE, a Boyden chamber system was utilized.
CBE at both 20 mg/ml and 50 mg/ml did not promote
migration of DU145 cells (Fig. 6). Significant increases
in directed migration of DU145 cells were observed in
response to 20 mg/ml FN.
Next, since the antibody to avb3 blocked CBE-
mediated attachment of DU145 cells, these cells were
evaluated for expression of mRNAs for av and b3. As
seen in Figure 7, DU145 cells expressed mRNAs for av
and b3. Given that OPN, a known ligand for avb3, is
present in CBE [11], and that OPN promotes cell mi-
gration [17], we evaluated the ability of OPN to pro-
Fig. 3. Effect of protein synthesis inhibition on DU145 cell at-
tachment. DU145 cells were incubated on tissue culture plates
(TCT) or plastic plates precoated with one of the following: water,
20 µg/ml fibronectin (FN), or 20 µg/ml crude bone extract (CBE).
Attachment conditions were duplicated with the addition of cy-
cloheximide (10 µg/ml) to the preincubation media. After 24 hr,
unattached cells were discarded, and attached cells were quanti-
tated with a Coulter counter. Data are expressed as mean ± SD
of triplicate plates (*P < 0.05 vs. no cycloheximide).
Fig. 4. Effects of RGD and RGE peptides on CBE-mediated at-
tachment of DU145 cells. DU145 cells were plated on tissue cul-
ture plates (TCT) or plastic plates precoated with 20 µg/ml fibro-
nectin (FN) or 20 µg/ml crude bone extract (CBE). Cell attach-
ment was further evaluated with the addition of RGD or RGE
peptides (100 µg/ml) to the preincubation media. After 24 hr,
unattached cells were removed and attached cells were quanti-
tated with a Coulter counter. RGD peptides abolished cell attach-
ment to CBE-coated plates. Data are expressed as mean ± SD of
triplicate plates (*P < 0.05 vs. respective control [no RGD or RGE
peptides]).
Fig. 5. Effect of antibodies directed against fibronectin or avb3
on CBE-mediated attachment of DU145 cells. DU145 cells were
plated on tissue culture plates (TCT) or plastic plates precoated
with 20 µg/ml fibronectin (FN) or 20 µg/ml crude bone extract
(CBE). Attached cells were quantitated after 24 hr with a Coulter
counter. CBE-mediated attachment was further characterized
with the addition to the preincubation media of an antibody to
avb3 (LM609), which blocked CBE-mediated attachment, or an
antibody to fibronectin (100 µg/ml) which was less effective at
blocking CBE-mediated attachment of DU145 cells. Note that the
antibody to fibronectin blocked FN-mediated attachment. Data
expressed as mean ± SD of triplicate plates (*P < 0.05 vs. control).
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mote migration of DU145 cells. As with CBE, no sig-
nificant increase in directed migration of DU145 cells
was observed in response to osteopontin (Fig. 6).
Effect of CBE on DU145 Cell Proliferation
To evaluate the mitogenic potential of CBE on
DU145 cells, a 4-day cell proliferation assay was uti-
lized in which DU145 cell proliferation was deter-
mined by changes in cell number. As demonstrated in
Table I, media containing 2% serum significantly re-
duced cell number on day 4 when compared to cells
grown in media containing 10% serum. To determine
the effect of CBE, cells were grown in media contain-
ing 2% serum plus CBE at 20 mg/ml. The data dem-
onstrate that bone proteins inhibited DU145 cell pro-
liferation on day 4 (Table I). The number of DU145
cells present in the CBE-containing media was re-
duced by 28% on day 4 when compared to the number
of cells present in the media containing 2% serum
alone. This reduction was statistically significant
(P < 0.05). No significant differences in DU145 cell
proliferation were noted between treatment groups at
early time points, i.e., on days 1 or 2. To investigate the
possibility that CBE was toxic to the cells, trypan blue
exclusion was evaluated on day 4, with >99% exclu-
sion of the dye in all treatment groups, indicating that
the antiproliferative effect of CBE was not due to cell
toxicity (data not shown).
DISCUSSION
Results from this study suggest that proteins lo-
cated in the mineralized compartment of bone facili-
tate adhesion of tumor cells and thus may play an
important role in the pathogenesis of bone metastases
in prostate cancer. LNCaP cells demonstrated a low
level of attachment under all conditions evaluated
when compared to DU145 cells. Thus, the DU145 cell
line was utilized for further study.
The bone protein extract utilized in this study was
previously demonstrated to contain a number of pro-
Fig. 6. Effects of CBE and GST-OPN on
DU145 cell migration. DU145 cell migration
(chemotactic activity) was evaluated with a
Boyden chamber assay. Migration toward FN
(20 µg/ml), and CBE or GST-OPN at 20 and
50 µg/ml, was evaluated at 3, 6, and 24 hr by
removing the membrane between the cham-
bers and gently swabbing the upper surface
to remove cells which had not migrated
through the pores in the membrane. Mi-
grated cells were quantitated with light mi-
croscopy in five nonoverlapping fields per
membrane. Data are expressed as mean fold
increase from control ± SEM of triplicate
plates. CBE and GST-OPN did not promote
DU145 cell migration. However, FN did pro-
mote migration of DU145 cells (*P < 0.005,
comparison of the mean migrated cell num-
ber between experimental and control con-
ditions [absence of putative chemotactic
agent]).
Fig. 7. Expression of av and b3 integrin subunit mRNAs in
DU145 and LNCaP cells. Total RNA (20 µg/lane) was analyzed by
Northern hybridization to 32P-labeled av and b3 probes. Note
that both cell lines express av mRNA, while only DU145 cells
express mRNA for the b3 subunit.
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teins, including fibronectin, bone salioprotein (BSP),
osteopontin (OPN), type I collagen, TGFb, IGF, PDGF,
and several bone morphogenic proteins [11,12]. Fibro-
nectin is known to support adhesion of a variety of
cells and indeed in the current study was utilized as a
positive control for attachment. However, fibronectin
is not solely responsible for the level of DU145 cell
attachment observed with CBE, as an antibody to FN
resulted in only a 38% reduction in CBE-mediated at-
tachment of DU145 cells. Importantly, the concentra-
tion of antibody appeared to be appropriate for block-
ing FN-mediated attachment, as this antibody nearly
abolished cell attachment in the FN-coated wells.
Other bone-associated proteins that may account for
the majority of the attachment activity of DU145 cells
include the RGD sequence, containing proteins OPN
and BSP. Several studies demonstrate that BSP and
OPN mediate cell attachment in an RGD-dependent
fashion [14,17–19].
In the present study, RGD peptides dramatically
inhibited cell attachment to CBE-coated dishes. This
result suggests that the peptides compete with RGD
sequences present in proteins within CBE, e.g., BSP
and OPN, for binding to receptors on DU145 cells.
RGD peptides also significantly reduced fibronectin-
mediated attachment, but to a lesser extent than RGD
blockade of CBE-mediated attachment (27% for FN vs.
98% for CBE). The modest effect of RGD peptides on
fibronectin-mediated attachment is in agreement with
several other studies, and suggests that attachment of
DU145 cells to fibronectin can occur via non-RGD mo-
tifs [20–22].
In order to provide further evidence that the bone-
associated proteins, BSP and OPN, are involved in
CBE-mediated attachment, the role of a cell surface
receptor known to bind to BSP and OPN, the integrin
avb3 [19], was evaluated. DU145 cells were found to
express mRNA for both av and b3. This result sup-
ports the findings of Witkowski et al. [23], which dem-
onstrated cell surface expression of av and b3 on
DU145 cells with FACS analysis. To address the con-
tribution of avb3 in adhesion of cells to CBE-coated
dishes, a blocking antibody to avb3 (LM609) [24] was
utilized. LM609 dramatically reduced CBE-mediated
cell adhesion, while this antibody did not alter fibro-
nectin-mediated attachment. Collectively, these re-
sults suggest that RGD-containing bone proteins, in
addition to fibronectin, are major mediators in the at-
tachment of DU145 cells to CBE.
The observed delay in attachment of DU145 cells to
the CBE-coated wells, when compared to fibronectin-
coated wells, suggests that CBE stimulates the synthe-
sis and/or transport of cell surface receptors from in-
tracellular compartments to the plasma membrane.
This hypothesis is supported by the results in which
the protein synthesis inhibitor, cycloheximide, nearly
eliminated cell adhesion in CBE-coated wells, while
substantial cell adhesion was still observed in fibro-
nectin-coated wells. Although the cycloheximide re-
sults indicate that protein synthesis is required, fur-
ther studies are needed to delineate the precise mecha-
nism(s) involved in CBE-mediated attachment of
DU145 cells.
The spreading of prostate tumor cells on bone pro-
teins observed in this study extends the results of Haq
et al. [3], who demonstrated that prostate tumor cells
preferentially adhered to bone marrow-derived endo-
thelial cells. Data from the present study suggest that
following diapedesis, prostate tumor cells can then di-
rectly adhere to the surrounding trabecular bone. Ad-
hesion of cells to extracellular matrix proteins is rec-
ognized as influencing several fundamental aspects of
cell function, including survival and differentiation
[25]. Although tumor cell adhesion to sinusoidal en-
dothelium is likely important in initiating secondary
tumors in bone, the role of adhesion to bone matrix
proteins for tumor growth is less clear. The mineral-
ized compartment of bone contains a wide variety of
growth factors which may facilitate the survival of
tumor cells in the absence of adhesion [26]. In addi-
tion, hematopoietic and bone cells may secrete a vari-
ety of factors which promote tumor cell growth. In-
deed, factors produced by bone fibroblasts [4], osteo-
blast-like cells [5], and factors present in bone marrow
[27] have been demonstrated to enhance prostate tu-
mor cell proliferation. Although the importance of tu-
mor cell adhesion in the extravascular space of bone
for tumor growth is not certain, we propose that
through direct attachment to bone or adjacent extra-
cellular matrix, tumor cells may have a greater impact
on bone homeostasis due to an increase in proximity
to bone cells and/or through receptor binding signal-
TABLE I. Effect of CBE on DU145 Cell Number†
Conditions Day 1 Day 2 Day 4
10% serum 7.48 ± 0.38 14.33 ± 2.35 77.96 ± 3.63
2% serum 7.54 ± 0.41 15.02 ± 0.87 67.79 ± 1.96*
2% serum/CBE 7.66 ± 0.61 14.34 ± 1.33 48.72 ± 4.94**
†DU145 cells (5,000/plate) were incubated overnight in media
with 10% FBS. On day 0, cells were then grown under the fol-
lowing conditions: 10% FBS, 2% FBS, or 2% FBS plus 20 mg/ml
crude bone extract (CBE). Plates were rinsed and cells removed
with trypsin/EDTA for Coulter counter measurement of cell
number on days 1, 2, and 4. Data are expressed as cell number
(×103) ± SD of triplicate plates.
*Statistically significant when compared to 10% serum
(P < 0.05).
**Statistically significant when compared to 2% serum
(P < 0.05).
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ing processes. Receptor-mediated events may enhance
the release of factors by tumor cells that act in a para-
crine fashion to alter the dynamics of bone cells.
In contrast to the attachment findings, results indi-
cate that bone protein extract and OPN are not che-
motactic for DU145 cells. These findings were surpris-
ing, given that products from resorbing bone and
OPN alone have been demonstrated to promote mi-
gration of breast cancer cells [17,28]. In addition, the
avb3 integrin, which is expressed by DU145 cells, cor-
related with migration toward OPN in vascular
smooth muscle cells [29]. These observations suggest
that, unlike vascular smooth muscle cells, the expres-
sion of avb3 by DU145 cells is not correlated with
migration toward OPN. The lack of a chemotactic re-
sponse by DU145 cells toward bone proteins observed
in this study may not be reflective of chemotactic re-
sponses in all prostate cancer cells. However, this re-
sult does suggest that this particular cell line lacks
appropriate receptors and/or signaling components
to trigger migration in response to bone proteins. Al-
ternatively, the bone protein extract utilized in this
study may contain both pro- and antimigration fac-
tors, with the antimigration factors predominating.
Although other promigration factors may be present
in the bone extract, such as FN, OPN is not a promi-
gration factor for DU145 cells.
Given the level of growth factors present in bone
matrix, a reduction in cell number by CBE was sur-
prising. These results may relate to the findings of
Story et al. [30], who demonstrated that picomolar
concentrations of transforming growth factor betas
(TGFbs) have antiproliferative activity in normal and
hyperplastic prostate cells. Findings by Webber et al.
[31], in which TGFb was demonstrated to inhibit
growth of DU145 cells, also implicate TGFb in the
antiproliferative effect of CBE on DU145 cell prolifera-
tion. TGFs are stored at high concentrations in bone
matrix [26] and thus may provide sufficient antipro-
liferative signals to counteract the known mitogenic
stimulus of other growth factors present in bone [6].
However, the pathogenesis of human prostate cancer
indicates that prostate tumor cells proliferate in bone.
The complexities of the proliferative response by tu-
mor cells in the bone/bone marrow environment are
yet to be elucidated, but may provide valuable insight
for the development of potential therapeutic strategies
for reducing the growth rate of prostate cancer cells in
bone.
In conclusion, the results obtained in this study in-
dicate that proteins present in mineralized bone pro-
mote the attachment of a human prostate cancer cell
line in vitro. These results suggest that bone proteins
play a key role in vivo during the development of
metastatic prostate lesions in bone. Although we are
beginning to gain some insight into the mechanisms of
preferential metastasis of prostate cancer cells to bone,
further investigation is needed to elucidate the mecha-
nism(s) involved in the disruption of bone homeosta-
sis.
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